GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heidelberg Pharma AG (XTER:HPHA) » Definitions » Other Long Term Assets

Heidelberg Pharma AG (XTER:HPHA) Other Long Term Assets : €0.81 Mil (As of Feb. 2025)


View and export this data going back to 2006. Start your Free Trial

What is Heidelberg Pharma AG Other Long Term Assets?

Heidelberg Pharma AG's other long-term assets for the quarter that ended in Feb. 2025 was €0.81 Mil.

Heidelberg Pharma AG's quarterly other long-term assets declined from Aug. 2024 (€0.98 Mil) to Nov. 2024 (€0.78 Mil) but then increased from Nov. 2024 (€0.78 Mil) to Feb. 2025 (€0.81 Mil).

Heidelberg Pharma AG's annual other long-term assets increased from Nov. 2022 (€0.01 Mil) to Nov. 2023 (€0.94 Mil) but then declined from Nov. 2023 (€0.94 Mil) to Nov. 2024 (€0.78 Mil).

Heidelberg Pharma AG Other Long Term Assets Historical Data

The historical data trend for Heidelberg Pharma AG's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heidelberg Pharma AG Other Long Term Assets Chart

Heidelberg Pharma AG Annual Data
Trend Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23 Nov24
Other Long Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.01 0.01 0.94 0.78

Heidelberg Pharma AG Quarterly Data
May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.97 0.98 0.98 0.78 0.81

Heidelberg Pharma AG Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Heidelberg Pharma AG Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heidelberg Pharma AG (XTER:HPHA) » Definitions » Other Long Term Assets
Comparable Companies
STU:T9G FRA:OMY XTER:MDG1 XTER:FYB VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX SMMT RPRX OCSE:GMAB XKRX:196170 INCY HKSE:02269
Traded in Other Exchanges
0QW5:UK
Address
Gregor-Mendel-Street 22, Ladenburg, DEU, 68526
Website
https://www.heidelberg-pharma.com
Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.
Executives
Walter Miller Board of Directors
Dr. Georg F. Baur Supervisory Board
Prof. Dr. Andreas Pahl Board of Directors

Heidelberg Pharma AG Headlines

No Headlines